The Rundown Weight-Loss Drugmakers Hit with Antitrust Lawsuit, Trump’s Plan Brings Down Energy Stocks
10 snips
Jan 16, 2026 A recent antitrust lawsuit targets Eli Lilly and Novo Nordisk over GLP-1 weight-loss drugs, shedding light on market dynamics. Netflix is making waves by expanding its deal with Sony and diving into video podcasts, aiming to capture exclusive content. In a major shift, energy stocks dropped after the White House introduced plans to stabilize power costs. Meanwhile, Wall Street reports record trading revenues while also facing significant job cuts. It's a whirlwind of topics that paint a complex picture of today’s market landscape.
AI Snips
Chapters
Transcript
Episode notes
Supreme Court Ruling Could Rock Markets
- The Supreme Court decision on Trump's tariffs could force refunds and raise market volatility.
- Investors should expect increased short-term market swings as legal clarity unfolds.
Host Quoted About Powell's 'Aura'
- Zaid Admani shared that he was quoted in the Wall Street Journal about Jerome Powell.
- He said the reporter ran with his line that Powell "has aura," which felt surreal to him.
GLP-1 Lawsuit Centers On Compounding Gray Area
- Strive Specialties sued Eli Lilly and Novo Nordisk alleging the pharma giants block low-cost compounded GLP-1s.
- The case hinges on compounding pharmacy rules, patent timelines, and a narrow exception for patient-specific doses.